Filters








106 Hits in 0.29 sec

FASTtrack: Pharmacology, 2nd edn by Michael D. Randall, David A. Kendall, Stephen PH Alexander. Published by Pharmacology Press, London, 2012. 288 pp, paperback price £22.99, ISBN: 978 0 85711 057 2

Clive Page
2013 British Journal of Clinical Pharmacology  
Clive Page Institute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 100 Stamford Street, Waterloo Campus, London SE1 9NH, UK  ... 
doi:10.1111/j.1365-2125.2012.04371.x fatcat:2mwiwnumffb4zkgqn5oyinhjoa

New Drugs and Targets for Asthma and Chronic Obstructive Pulmonary Disease (CDPD)

Clive Page
2011 British Journal of Clinical Pharmacology  
doi:10.1111/j.1365-2125.2010.03886.x pmcid:PMC3099391 fatcat:fuiea76qenflfmcdc4zu3xn3a4

Heparin and Related Drugs: Beyond Anticoagulant Activity

Clive Page
2013 ISRN Pharmacology  
Page, F. J. Van Der Meer, and P. J.  ...  Page, "Heparin inhibits allergeninduced eosinophil infiltration into guinea-pig lung via a mechanism unrelated to its anticoagulant activity, " Pulmonary Pharmacology & Therapeutics, vol. 14, no.  ... 
doi:10.1155/2013/910743 pmid:23984092 pmcid:PMC3747464 fatcat:qqnrmxtq5rhgxgs45rn6iaruim

A response to: 'A manifesto for clinical pharmacology from principles to practice' by Jeff Aronson

Clive Page
2010 British Journal of Clinical Pharmacology  
There are many of my clinical colleagues who would surely satisfy point 2 in the summary on page 3 of Aronson's article as they are specialists in their chosen therapeutic and disease areas, but who certainly  ... 
doi:10.1111/j.1365-2125.2010.03769.x pmid:21175448 pmcid:PMC3014076 fatcat:2yfxckmqincp3czh4hskvcij34

Extracellular matrix composition influences the resistance of airway remodelling events towards glucocorticoid treatment

Simon Pitchford, Clive Page
2003 British Journal of Pharmacology  
doi:10.1038/sj.bjp.0705136 pmid:12711613 pmcid:PMC1573764 fatcat:d5mf3wxazja7zhj3ju5gnhn2te

An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD

Mario Cazzola, Clive Page
2018 European Respiratory Journal  
appropriate investigations is required before we have a proper understanding of the real role that RPL554 could have in the treatment of COPD http://ow.ly/pjte30m128c Cite this article as: Cazzola M, Page  ... 
doi:10.1183/13993003.01675-2018 fatcat:zft2uonaszhd5dw7zdydkhcoay

Sir David Jack: an extraordinary drug discoverer and developer

Clive Page, Patrick Humphrey
2013 British Journal of Clinical Pharmacology  
Gut 1980; 21: 408-12. 9 Cazzola MC, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450-504. 10 Barnes PJ, Breckenridge A.  ...  Thorax 1988; 43: 674-8. 6 Page CP. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by B 2 agonists. Lancet 1991; 337: 717-20. 7 Lemanske RF, Busse WW.  ... 
doi:10.1111/j.1365-2125.2012.04467.x pmid:22994263 pmcid:PMC3635591 fatcat:5k3pewbvjjhbbnef7gopwiy7yi

Roflumilast: a novel phosphodiesterase 4 inhibitor for the treatment of inflammatory airways disease

Victoria Boswell-Smith, Clive P Page
2007 Therapy  
Isoenzyme phosphodiesterase 4 inhibitors are novel therapeutic agents in late clinical development for the treatment of chronic obstructive pulmonary disease and asthma, both diseases with significant unmet treatment needs. Roflumilast is one such isoenzyme phosphodiesterase 4 inhibitor that is undergoing Phase III clinical development. It is an orally active compound that owes part of its efficacy and long duration of action to its primary metabolite roflumilast N-oxide. Preclinical and
more » ... clinical and clinical studies have indicated that its probable mechanism of action is anti-inflammatory, although it may also have the ability to relax airway smooth muscle. Its relatively low incidence of class-associated gastrointestinal events and long duration of action may account for its improved therapeutic profile over other agents in its class.
doi:10.2217/14750708.4.2.153 fatcat:mz5rizzadnfrzeavkglnpua6da

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors

Katharine H. Banner, Clive P. Page
1996 Allergology International  
Chem. 1976; 251: 4922-9. 24 Banner KH, Roberts N, Page CP.  ...  Barnes PJ, Chung KF, Page CP. Inflammatory mediators and asthma. Pharmacol. Rev. 1988; 40: 49-84. 49 Yukawa T, Kroegel C, Dent G, Chanez P, Ukena D, Barnes PJ.  ... 
doi:10.2332/allergolint.45.125 fatcat:hadx4ktw6jfbvpy5cddpemzsly

Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs

Katharine H. Banner, Clive P. Page
1995 British Journal of Pharmacology  
Pharmacology (1995 Pharmacology ( ) 114. 93-98 . 1995 Stockton Press All rights reserved 0007-1188/95 $9.00 M Part of this work has been presented to the British Pharmacological Society (Banner & Page  ...  airways (Corrigan & Kay, 1989) can also be inhibited by mixed type III/IV PDE inhibitors (Robicsek et al., 1991; Schudt et al., 1992) and by type IV PDE inhibitors (Averill & Kammer, 1985; Banner & Page  ... 
doi:10.1111/j.1476-5381.1995.tb14910.x pmid:7536098 pmcid:PMC1510161 fatcat:mpf7kf23hbatfhi7iyen2utf4y

Effect of heparin on antigen-induced airway responses and pulmonary leukocyte accumulation in neonatally immunized rabbits

Janet M H Preuss, Clive P Page
2000 British Journal of Pharmacology  
doi:10.1038/sj.bjp.0703247 pmid:10780962 pmcid:PMC1572004 fatcat:bmq2ejqcofadpeswo2lfpkl4da

The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin

Helen Jones, William Paul, Clive P Page
2002 British Journal of Pharmacology  
inhibited PAF-and antigeninduced eosinophil accumulation in the lung and aerosolized heparin inhibited antigen-induced eosinophil (but not neutrophil) pulmonary accumulation in the same model (Seeds & Page  ...  mediated early asthmatic response in subjects with atopic asthma (Diamant et al., 1996) or acute bronchospasm in the airways of allergic guinea-pigs (Howell & Woeppel, 1993) or rabbits (Preuss & Page  ... 
doi:10.1038/sj.bjp.0704505 pmid:11815383 pmcid:PMC1573160 fatcat:bt3ih4oixzfbnmkmwedoashmoq

Regulation of platelet function by catecholamines in the cerebral vasculature of the rabbit

Michael Emerson, William Paul, Clive P Page
1999 British Journal of Pharmacology  
In vitro platelet aggregation is, however, poorly predictive of platelet function in vivo (Morley & Page, 1984) and we have shown here that, in our model, there is no signi®cant eect of either pre-treatment  ... 
doi:10.1038/sj.bjp.0702671 pmid:10455322 pmcid:PMC1566137 fatcat:g6eezei4cnfyxpvq5hes2izasu

Doxofylline is not just another theophylline!

Maria Gabriella Matera, Clive Page, Mario Cazzola
2017 International Journal of COPD  
Doxofylline, which differs from theophylline in containing the dioxalane group at position 7, has comparable efficacy to theophylline in the treatment of respiratory diseases, but with an improved tolerability profile and a favorable risk-to-benefit ratio. Furthermore, it does not have significant drug-drug interactions as exhibited with theophylline, which make using theophylline more challenging, especially in elderly patients with co-morbidities receiving multiple classes of drug. It is now
more » ... of drug. It is now clear that doxofylline also possesses a distinct pharmacological profile from theophylline (no significant effect on any of the known phosphodiesterase isoforms, no significant adenosine receptor antagonism, no direct effect on histone deacetylases, interaction with β 2 -adrenoceptors) and therefore, should not be considered as just a modified theophylline. Randomized clinical trials of doxofylline to investigate the use of this drug to reduce exacerbations and hospitalizations due to asthma or COPD as an alternative to expensive biologics, and certainly as an alternative to theophylline are to be encouraged.
doi:10.2147/copd.s150887 pmid:29255355 pmcid:PMC5723117 fatcat:egznwyfot5f4nofkgqsbsriu3m

Phosphodiesterase inhibitors

Victoria Boswell-Smith, Domenico Spina, Clive P Page
2009 British Journal of Pharmacology  
Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this contributed toward their clinical efficacy was poorly defined. However, the discovery of 11 isoenzyme families and our increased understanding of
more » ... nderstanding of their function at the cell and molecular level provides an impetus for the development of isoenzyme selective inhibitors for the treatment of various diseases. This review focuses on the development of PDE3 inhibitors for congestive heart failure, PDE4 inhibitors for inflammatory airways disease and most successfully, PDE5 inhibitors for erectile dysfunction PDE3 has high affinity for cAMP but can also hydrolyse cGMP. However, it hydrolyses cAMP at 10 times the rate it hydrolyses cGMP and therefore cGMP effectively acts as a competitive inhibitor for cAMP and consequently for PDE3 (Lugnier, 2005) . As a result of its high expression in both the vasculature and the airways, PDE3 was identified as a potential therapeutic target in cardiovascular disease and
doi:10.1038/sj.bjp.0706495 pmid:16402111 pmcid:PMC1760738 fatcat:64oyeoa5c5ddbd4yjp66svh37a
« Previous Showing results 1 — 15 out of 106 results